COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04617002
Expanded Access Status : Available
First Posted : November 5, 2020
Last Update Posted : December 3, 2020
Information provided by (Responsible Party):
Oncoceutics, Inc.

Tracking Information
First Submitted Date October 29, 2020
First Posted Date November 5, 2020
Last Update Posted Date December 3, 2020
Descriptive Information
Brief Title Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Brief Summary This is an intermediate-size expanded access protocol to provide ONC201 to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 through clinical trials.
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Intermediate-size Population
Intervention Drug: ONC201
ONC201 is an oral, small molecule selective antagonist of DRD2
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status Available
Contact: Clinical Operations Oncoceutics 1-844-ONCORXS
Listed Location Countries United States
Removed Location Countries  
Administrative Information
NCT Number NCT04617002
Responsible Party Oncoceutics, Inc.
Study Sponsor Oncoceutics, Inc.
Collaborators Not Provided
Investigators Not Provided
PRS Account Oncoceutics, Inc.
Verification Date December 2020